Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Psilocybin in Amyotrophic Lateral Sclerosis: NCT06656702 Clinical Landscape Report 2026
15 October 2026
NCT06656702 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TUB-030 in Advanced Malignant Solid Neoplasm: NCT06657222 Clinical Landscape Report 2026
15 October 2026
NCT06657222 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06651853 Clinical Landscape Report 2026
15 October 2026
NCT06651853 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Abacavir sulfate/Dolutegravir sodium/Lamivudine in Amyotrophic Lateral Sclerosis: NCT06658977 Clinical Landscape Report 2026
15 October 2026
NCT06658977 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rezetamig in High grade B-cell lymphoma: NCT06660563 Clinical Landscape Report 2026
15 October 2026
NCT06660563 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Renal Pelvis Carcinoma: NCT06661720 Clinical Landscape Report 2026
15 October 2026
NCT06661720 clinical landscape for Renal Pelvis Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ICG-99mTc-nanoscan in Melanoma: NCT06666634 Clinical Landscape Report 2026
15 October 2026
NCT06666634 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Refractory Melanoma: NCT06660420 Clinical Landscape Report 2026
15 October 2026
NCT06660420 clinical landscape for Refractory Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Talimogene laherparepvec in Locally Advanced Soft Tissue Sarcoma: NCT06660810 Clinical Landscape Report 2026
15 October 2026
NCT06660810 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
AMX-0114 in Amyotrophic Lateral Sclerosis: NCT06665165 Clinical Landscape Report 2026
15 October 2026
NCT06665165 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06664411 Clinical Landscape Report 2026
15 October 2026
NCT06664411 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06665217 Clinical Landscape Report 2026
15 October 2026
NCT06665217 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.